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OBJECTIVE—Various methods are used to quantify postpran-
dial glycemia or glucose variability, but few have been compared
and none are standardized. Our objective was to examine the
relationship among common indexes of postprandial glycemia,
overall hyperglycemia, glucose variability, and A1C using de-
tailed glucose measures obtained during everyday life and to
study which blood glucose values of the day provide the stron-
gest prediction of A1C.
RESEARCH DESIGN AND METHODS—In the A1C-Derived
Average Glucose (ADAG) study, glucose levels were monitored
in 507 participants (268 type 1 diabetic, 159 type 2 diabetic, and
80 nondiabetic subjects) with continuous glucose monitoring
(CGM) and frequent self-monitoring of blood glucose (SMBG)
during 16 weeks. We calculated several indexes of glycemia and
analyzed their intercorrelations. The association between glu-
cose measurements at different times of the day (pre- and
postprandial) and A1C was examined using multiple linear
regression.
RESULTS—Indexes of glucose variability showed strong inter-
correlation. Among postprandial indexes, the area under the
glucose curve calculated from CGM 2 h after a meal correlated
well with the 90-min SMBG postprandial measurements. Fasting
blood glucose (FBG) levels were only moderately correlated with
indexes of hyperglycemia and average or postprandial glucose
levels. Indexes derived with SMBG strongly correlated with
those from CGM. Some SMBG time points had a stronger
association with A1C than others. Overall, preprandial glucose
values had a stronger association with A1C than postprandial
values for both diabetes types, particularly for type 2 diabetes.
CONCLUSIONS—Indexes of glucose variability and average
and postprandial glycemia intercorrelate strongly within each
category. Variability indexes are weakly correlated with the
other categories, indicating that these measures convey different
information. FBG is not a clear indicator of general glycemia.
Preprandial glucose values have a larger impact on A1C levels
than postprandial values. Diabetes 59:1585–1590, 2010
N
ew treatment regimens and guidelines have
increasingly focused on postprandial hypergly-
cemia as an additional target beyond average
glucose control (1). However, direct evidence
for an effect of speciﬁcally controlling postprandial glu-
cose (PPG) and glucose excursions (over and above the
effect of reducing average glucose levels on long-term
diabetes complications) is limited. The current debate
about whether postprandial hyperglycemia and excessive
glucose variability are associated with an increased risk of
diabetes complications is largely based on epidemiological
studies (2–6). Many of these ﬁndings (2,4–6) are based on
an extrapolation of glucose levels 2 h after an oral glucose
tolerance test (OGTT) as a model for the postprandial
state rather than on “real-life” PPG measurements. Only a
few studies (4,7,8) have also measured the effect of A1C
for comparison, and these show conﬂicting results.
Studies examining PPG control use various methods to
quantify PPG, overall hyperglycemia, and glucose variabil-
ity (9), without any standardization of methods. One
approach to assess the role of PPG has been to examine
the extent to which it contributes to overall glucose
exposure, measured as A1C (10–13). Limited evidence
suggests that postprandial glycemia is the dominant con-
tributor to overall hyperglycemia in patients with good to
moderate glycemic control (A1C 8.5%), while fasting
glucose levels represent the major contributor at higher
A1C levels (14). These ﬁndings have been used to support
the need to measure and treat PPG in order to reach
clinical guideline levels of A1C (15,16). Measures of noc-
turnal glycemia are rarely used in the prediction of A1C.
Available literature exploring the nocturnal glucose expo-
sure is sparse and mostly focused on nocturnal hypogly-
cemia or assessment of glucose variability during glucose-
lowering therapies.
Our aim was to examine the relationship among the most
commonly used indexes of PPG, overall hyperglycemia,
glucose variability, nocturnal glycemia, and A1C using glu-
cose measures obtained during everyday activities from the
A1C-Derived Average Glucose (ADAG) study. Additionally,
we studied which blood glucose value(s) of the day provide
the strongest prediction of mean blood glucose, as measured
by A1C, especially focusing on pre- and postprandial glucose
contributions to mean blood glucose levels.
RESEARCH DESIGN AND METHODS
The ADAG study was conducted at 10 centers in the U.S., Europe, and Africa
from 2006 to 2008 to deﬁne the relationship between A1C and average glucose
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diabetes.diabetesjournals.org DIABETES, VOL. 59, JULY 2010 1585levels. A full description of the study has been published (17). A total of 268
individuals with type 1 diabetes, 159 individuals with type 2 diabetes, as well
as 80 nondiabetic control subjects (aged 18–70 years) completed the study.
Participants were selected based on stable glycemic control as evidenced by
two A1C values within one percentage point of each other in the 5 months
prior to recruitment. Individuals with a wide range of A1C levels were
included. The nondiabetic control subjects had a plasma glucose level 5.4
mmol/l (97 mg/dl) after overnight fasting, A1C levels 6.5%, and no history of
diabetes or use of antidiabetes medication. The study was approved by the
human studies ethical committees at the participating institutions, and
informed consent was obtained from all participants.
Measurements of glycemia. During the study period, levels of glucose
concentrations were assessed through three different methods. Continuous
interstitial glucose monitoring (Medtronic Minimed, Northridge, CA) was
performed four times with 4-week intervals during the 16-week study period.
Monitoring periods lasted at least 48 h, during which time glucose levels were
assessed every 5 min. Continuous glucose monitoring (CGM) data were
accepted for analysis if there were no gaps longer than 120 min and if the
mean absolute difference with the Hemocue calibration results was 18%, as
recommended by the manufacturer.
For calibration purposes, and for measurement of pre- and postprandial
glycemia, participants performed an eight-point self-monitoring of blood
glucose (SMBG) proﬁle (preprandial, 90 min postprandial, bedtime, and 3:00
A.M.) with the HemoCue meter (Hemocue Glucose 201 Plus; Hemocue,
A ¨ngelholm, Sweden) during the days of CGM. In addition, during the weeks
when CGM was not performed, subjects performed a seven-point SMBG (the
same as the eight-point proﬁle above without the 3:00 A.M. measurement)
(OneTouch Ultra; LifeScan, Milipitas, CA) for at least 3 days per week.
All blood glucose values stated are plasma equivalents. Blood samples
were analyzed for A1C levels with four different Diabetes Control and
Complications Trial–aligned assays: a high-performance liquid chromatogra-
phy assay, two immunoassays, and an afﬁnity assay (all approved by the
National Glycohemoglobin Study Program). The mean value at the end of the
12-week study period was used (17).
Calculated indexes of glycemia. Indexes of glucose variability and post-
prandial glucose levels were calculated from the glucose monitoring data. The
average blood glucose and SD were calculated based on CGM data and the
seven-point SMBG (LifeScan) data. A combined average blood glucose was
calculated from CGM and SMBG, weighted by the days of monitoring for each.
Indexes based on CGM were calculated after exclusion of the initial2ho f
monitoring, which is considered to be an unstable calibration period.
Two indexes of intraday glucose variability were calculated based on CGM:
the mean amplitude of glycemic excursions (MAGE) and the continuous
overlapping net glycemic action (CONGA). MAGE is the mean of the differ-
ences between consecutive peaks and nadirs, only including changes of 1S D
of glycemic values and thus capturing only major ﬂuctuations (18,19). For
the calculation of CONGAn, the difference of the current observation and the
observation n hours previously is calculated for each observation after the
ﬁrst n hours. The CONGAn is the SD of these differences (19). We analyzed
CONGA for 1, 2, and 4 h. Both high MAGE and CONGA values indicate high
intraday glucose variability.
As an indicator of overall hyperglycemia, the 24-h cumulative exposure to
glucose levels above different thresholds was calculated as the area under the
curve (AUC) of CGM above levels of 7.0, 11.1, and 16.7 mmol/l (or 126, 200,
and 300 mg/dl, respectively). This was done for the ﬁrst 24 h of each CGM
period after the initial calibration period. Indexes of nocturnal blood glucose
were calculated as the mean blood glucose from the CGM period 6 h prior to
the fasting blood glucose (FBG) measurement. Furthermore, for each individ-
ual, a mean of all 3:00 A.M. SMBGs (HemoCue) was calculated. Also from CGM,
a postprandial AUC (AUCpp) was calculated for periods of 2 or 4 h after a meal
(without blood glucose thresholds), and the postprandial increment was
calculated from the preprandial glucose level to the highest peak for periods
of 2 or 4 h after a meal. Finally, pre- and postprandial measurements from
SMBG (HemoCue) were used to calculate mean pre- and postprandial blood
glucose, as well as pre- and postbreakfast, lunch, and dinner values. The
prebreakfast blood glucose was used as the FBG.
Statistical analyses. The Pearson correlation coefﬁcient (r) was computed
for each pair of glycemic indexes. This was done including only the diabetic
population, as the measurements from nondiabetic participants inﬂate the
correlations. Scatterplots of all pairs are presented with an indicator of the
Pearson correlation coefﬁcient (r).
A1C was modeled by multiple linear regression using SMBG measure-
ments at different times of the day as explanatory variables. The associa-
tion to A1C was examined in three separate analyses, including glucose
before and after main meals, mean of all pre- and postmeal glucose
measures, and adding nocturnal (3:00 A.M.) SMBG. These models were
ﬁtted for all individuals with diabetes and separately for type 1 and type 2
diabetes treated with and without insulin. We deﬁned the proportion of
A1C variation (SD) explained by each model as the difference between
the A1C SD for each subgroup and the residual SD of the model divided by
the SD.
RESULTS
Glucose monitoring in the ADAG study was completed by
507 participants. Approximately 2,700 glucose values from
each participant were available for analysis. We excluded
10 nondiabetic participants from the analyses of average
SMBG and SDs due to missing LifeScan measurements and
1 participant with type 1 diabetes due to erroneous,
extreme HemoCue measurements of pre- and postprandial
values.
Characteristics of the study population are summarized
in Table 1. A1C levels were higher among those with type
1 diabetes (7.3 vs. 6.8% for type 2 diabetes, P  0.01). Also,
the degree of variability, expressed as the SD of the CGM
or SMBG measurements and the calculated MAGE and
CONGA, was higher among individuals with type 1 diabe-
tes compared with those with type 2 diabetes or nondia-
betic individuals (P  0.01).
As an indicator of overall hyperglycemia, the 24-h cu-
mulative exposure to glucose levels above selected glu-
cose thresholds was calculated as the AUC of glucose
(AUC [in hours  mmol/l]) by subgroups deﬁned by type
of diabetes and, for type 2 diabetes, insulin therapy. In
each subgroup, a different proportion of participants
reached each respective threshold at least at some point
during the CGM period. While 80% of those with type 1
diabetes and 63% of those with type 2 diabetes on insulin
treatment reached a level of 16.7 mmol/l (300 mg/dl), only
31% of those with type 2 diabetes without insulin treat-
ment did so. One individual without diabetes reached this
level brieﬂy. (These results can be seen in the online
appendix Table, available at http://diabetes.diabetes
journals.org/cgi/content/full/db09-1774/DC1).
The relationship between the different indexes of glyce-
mia is illustrated in pairwise scatterplots in Fig. 1 (and in
an extended online appendix Fig. 2). Although the differ-
ent indexes were strongly correlated within each category,
some indexes do capture somewhat different information.
All glucose variability indexes calculated from CGM were
closely correlated. CONGA analyses for 1, 2, and 6 h
correlated to CONGA4h with correlation coefﬁcients of
0.94, 0.98, and 0.99, respectively (data not shown).
CONGA4 and CGM SD (not shown) were both strongly
correlated with MAGE (r  0.95). The SMBG variability
index (SD) correlated with the CGM indexes MAGE, the
CGM SD, and the CONGA4, with coefﬁcients of 0.83, 0.86,
and 0.83, respectively. The variability measures did not
correlate well with the postprandial measurements or
indexes of fasting or average glycemia (illustrated in
Supplemental Fig. 2 in the online appendix). The postpran-
dial indexes calculated from CGM 2 or 4 h after meal,
AUCpp2 and AUCpp4, were strongly correlated (r  0.97)
and correlated well with the SMBG postprandial measure-
ments (r  0.92 and 0.89, respectively) (only AUCpp2 is
shown). The postprandial increment, from preprandial
blood glucose level to highest blood glucose peak within a
2- or 4-h postprandial window, did not correlate well with
any other measure. The correlation coefﬁcients with
SMBG postprandial measurements were as low as 0.51.
The nocturnal blood glucose mean from CGM and the
self-monitored 3:00 A.M. “random” night blood glucose
correlated by a correlation coefﬁcient of 0.83.
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A1C levels. Among participants with type 1 diabetes,
prebreakfast, prelunch, and postlunch blood glucose mea-
surements had the largest effect on A1C. Among partici-
pants with type 2 diabetes, prebreakfast, postlunch, and
predinner values had the largest effects on A1C, regardless
of insulin treatment. In general, the mean of all preprandial
values predicted A1C better than the mean of all postpran-
dial values among those with either type of diabetes both
before and after adding nocturnal blood glucose to the
model (statistical signiﬁcant difference [P  0.05] for the
total diabetic group but not for diabetic subgroups or
the nondiabetic group). The proportion of A1C variation
(SD) explained by the glucose features of each model can
be seen in Table 2 and can be compared with variation
explained by average blood glucose. Adding a nocturnal
glucose index (3:00 A.M. SMBG) only minimally increased
the proportion of variation explained.
DISCUSSION
Based on frequent glucose monitoring during usual daily
activities, we found, in a large set of individuals with type
1 diabetes, type 2 diabetes, or those without diabetes, that
many of the commonly used indexes of glycemic variabil-
ity, average glycemia, and postprandial glycemia were
strongly correlated within each category. Indexes of glu-
cose variability (CONGA, SD of CGM or SMBG, and
MAGE) were especially highly correlated. These ﬁndings
indicate that the different methods of characterizing glu-
cose variability tend to convey similar information.
The putative roles of glucose variability and PPG as risk
factors for diabetes complications are based on 1) studies
reporting an association between excessive PPG levels
and factors that may lead to development of diabetes
complications (20–23), 2) epidemiological studies associ-
ating 2-h post-OGTT values with increased mortality and
cardiovascular disease (2–5), and 3) a few clinical trials in
very speciﬁc subgroups (e.g., pregnant women [24] and
individuals with impaired glucose tolerance [25] or type 2
diabetes post-AMI [26]), which have addressed the issue
with different methods and have had conﬂicting results.
The roles of PPG and glucose variability as risk markers
need further exploration, and an understanding of the
differences and similarities among the different measures
of PPG, overall hyperglycemia, and glucose variability is
critical.
MAGE (18) has previously been described as the gold
standard with which to measure variability (19,27). Our
ﬁndings show that CONGA or the “simple” SD captures
variability to a very similar degree as MAGE. Regarding
the methods to assess PPG, we found that the postprandial
AUC from CGM 2 h after a meal correlates well with SMBG
postprandial measurements, with a correlation coefﬁcient
of 0.92. This suggests that a routine 90-min postprandial
SMBG measurement contains much of the information
about the glucose curve in the hours after a meal. The
ADAG study also showed that seven-point proﬁle SMBG
levels, measured on average 3 days per week, and CGM,
measured on 2 days per month, both over a 3-month
period, predict average glucose and A1C similarly (17).
The postprandial increment in glucose levels (the differ-
ence from preprandial to highest postprandial value in a
2-h window) showed generally weak correlations with
postprandial blood glucose levels (r  0.45–0.51) and with
TABLE 1
Clinical and glycemic characteristics
All Type 1 diabetes Type 2 diabetes No diabetes
n 507 268 159 80
Age (years) 47.6  13.6 44.1  12.9 56.6  9.4 41  13.8
Sex (% female) 54 52 51 69
Ethnicity (% Caucasian) 82 91 74 68
BMI (kg/m
2)
Female 28.1  7 26.3  4.7 32.7  8.7 25.9  5.5
Male 27.6  5.1 26.1  3.4 30.8  6.2 25  3.3
Treatment with insulin 65 100 38 0
A1C (%) 6.8  1.3 7.3  1.1 6.8  1.1 5.2  0.3
FBG (mmol/l) 7.8  2.4 8.5  2.5 7.8  2.1 5.3  0.6
Average blood glucose (mmol/l) 8.3  2.2 9  2 8.3  2 5.6  0.4
CGM average (mmol/l) 8.5  2.2 9.3  2 8.5  2 5.8  0.6
SMBG average (mmol/l) 8.2  2.2 8.9  2.1 8.3  2 5.5  0.5
Nocturnal measures
Mean 3:00 A.M. SMBG (mmol/l) 8.1  2.7 9.2  2.7 7.6  2.3 5.6  0.7
Mean nocturnal blood glucose CGM (mmol/l) 8.0  2.3 8.9  2.3 7.8  2.1 5.6  0.6
Prandial measures
Preprandial SMBG (mmol/l) 7.7  2.1 8.4  2 7.6  1.9 5.4  0.5
Postprandial SMBG (mmol/l)* 9  2.4 9.7  2.1 9.4  2.2 6.1  0.7
AUCpp 2-h CGM (h/mmol/l) 17.6  4.5 19.1  4.1 17.8  41 2  1.4
PPG increment 2-h CGM (mmol/l)† 2.8  1.4 3.4  1.2 2.7  1.2 1.2  0.5
Variability measures
CGM SD (mmol/l) 2.7  1.4 3.6  0.9 2.2  0.9 0.8  0.2
SMBG SD (mmol/l)§ 3.2  1.5 4.1  1 2.6  1 1.1  0.4
MAGE (mmol/l) 4.8  2.4 6.4  1.8 3.8  1.5 1.4  0.5
CONGA4 (mmol/l) 3.7  1.9 4.9  1.3 2.9  1.2 1  0.3
Data are means  SD or percent. Glucose values are expressed as plasma equivalent mmol/l. *Deﬁned as mean of 90-min postprandial
self-monitored glucose levels. †Deﬁned as the increment from the preprandial blood glucose to highest peak 2-h postprandially. §Deﬁned as
the SDs of all self-monitored blood glucose.
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increments have been used to assess glucose variability
and PPG in other studies (14,28). The difference between
the calculated increments (from CGM) and the difference
between the pre- and postprandial measurements from
SMBG (Table 1) might be because the latter is measured
by the participant 90 min after eating (not necessarily
capturing the highest postprandial value). One might ex-
pect large postprandial increments to reﬂect high glucose
variability; however, the correlation with the variability
measures was also only moderate (r  from 0.41 [SMBG
SD] to 0.54 [CONGA4]).
As expected, A1C correlated well with average blood
glucose from CGM, SMBG, and the two combined. When
exploring the contribution of glucose levels from SMBG at
different times of the day to average glycemia (Table 3),
the preprandial glucose levels had a larger effect on A1C
than postprandial glucose levels, presumably because they
resemble the 24-h glucose levels (and thus the long-term
exposure to glucose) more closely. This result was the
same before and after including the nocturnal blood
glucose index to the regression model, which, surprisingly,
only lead to a small increase in the proportion of A1C
variation explained.
The frequently cited article by Monnier et al. (14)
concludes that postprandial glucose levels are the domi-
nant contributor to A1C levels in patients with A1C 8.5%,
while fasting glucose levels were the major contributor for
patients with A1C 8.5%. The calculations underpinning
this conclusion were based on AUCs derived from meal-
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FIG. 1. Pairwise scatter diagrams illustrating selected correlations of glycemic variables with Pearson correlation coefﬁcients (r) for each pair
of indexes (not including data for no diabetes), highlighting the different participant subgroups with different shades (type 1 diabetes, dark gray;
type 2 diabetes, light gray; and no diabetes, black).
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bution of glucose exposure outside meal periods to A1C.
Monnier et al. (14) deﬁne postprandial glycemia as the
AUC above each individual’s fasting value, while prepran-
dial glycemia is deﬁned as the AUC between 6.1 mmol/l
(110 mg/dl) and measured FBG for each individual. This
approach introduces a bias when comparing the associa-
tion between these two indexes and A1C. Individuals with
A1C levels 8.5% will strongly tend to also have high FBG.
Their postprandial AUC values will therefore be small by
artifact, as only excursions above these high individual
FBG values are considered postprandial glucose exposure.
Simultaneously, Monnier et al.’s deﬁnition yields larger
preprandial AUCs in this same group, thus introducing the
reported effect. This methodological problem might ex-
plain why Monnier et al.’s results differ from our ﬁndings
and those of others (12,29).
Our study shows that no single blood glucose measure-
ment during the day accurately predicts A1C. This is in
accordance with previous studies (29–31) showing that
single or limited numbers of blood glucose measurements
daily do not accurately reﬂect A1C levels. However, any
insights into the speciﬁc timed glucose measurement or
combination of measurements that have the largest effect
on A1C can help patients and clinicians to plan optimal
glucose-monitoring regimens.
Levels of FBG alone were not clear indicators of overall
hyperglycemia. The correlation coefﬁcients to indexes of
hyperglycemia and average or postprandial blood glucose
levels are between 0.60 and 0.70 in the present study. This
adds to previous ﬁndings (30,31) showing that A1C and
postchallenge blood glucose are difﬁcult to predict from
FBG values alone. Bouma et al. (30) found a correlation
coefﬁcient of 0.77 between A1C and FBG in 1,020 individ-
uals with type 2 diabetes.
This study is based on frequent glucose monitoring
during real-life activities in a large, heterogeneous popu-
lation of people with diabetes and those without diabetes
and provides the opportunity to assess reliably the differ-
ent features of glycemia. The limitations of the study are
that the ADAG study population was selected to exclude
patients with severe renal/liver disease, pregnancy, and
anemia. Therefore, the results may not be extrapolated to
all patients with diabetes. However, patients were chosen
to span a large range of A1C levels. Moreover, the ADAG
study recruited a broad multicenter population, so we feel
it is justiﬁable to draw general conclusions from our
results.
The fact that participants had stable A1C (1% A1C
change 6 months prior to study) could have lead to
underestimation of glucose variability. However, high lev-
els of glucose variability were seen among our subjects
despite stable A1C levels. Even though type 1 diabetes and
type 2 diabetes have different glucose patterns due to
different disease mechanisms, the mechanism of hemoglo-
bin glycation is likely to be the same. The correlation of
the glycemic indexes were therefore calculated for the
combined group. Limitations of the MiniMed CGM system
include the inability to measure glucose values 2.2
mmol/l (40 mg/dl) or 22.2 mmol/l (400 mg/dl) (measure-
ments outside this range were treated as 2.2 or 22.2
mmol/l, respectively, for the analyses). The mean FBG is
derived from prebreakfast measurements and thus can
contain blood glucose not preceded by8ho ffasting.
In summary, the role of glucose excursions and post-
prandial glycemia in day-to-day diabetes control and risk
TABLE 2
Effects of speciﬁc glucose measurements and A1C in three multiple linear regression models
All diabetes (n  427)
Type 1 diabetes
(n  268)
Type 2 diabetes
(n  99)
Type 2 diabetes
(n  60)
Non–insulin-treated Insulin-treated
A
Prebreakfast 0.122 (0.086–0.157)* 0.107 (0.065–0.149)* 0.116 (0.031–0.201)* 0.179 (0.088–0.270)*
Postbreakfast 0.020 (0.011 to 0.050) 0.000 (0.37 to 0.038) 0.029 (0.035 to 0.093) 0.078 (0.008–0.148)*
Prelunch 0.097 (0.059–0.134)* 0.130 (0.086–0.175)* 0.055 (0.053 to 0.164) 0.002 (0.088 to 0.091)
Postlunch 0.108 (0.071–0.145)* 0.120 (0.077–0.164)* 0.092 (0.009 to 0.192) 0.103 (0.015–0.191)*
Predinner 0.093 (0.058–0.128)* 0.053 (0.012–0.095)* 0.085 (0.034 to 0.204) 0.140 (0.052–0.229)*
Postdinner 0.052 (0.018–0.085)* 0.077 (0.037–0.117)* 0.066 (0.021 to 0.153) 0.012 (0.109 to 0.085)
A1C variation explained† 41% 39% 49% 43%
B
All preprandial 0.315 (0.267–0.362)* 0.288 (0.227–0.349)* 0.259 (0.164–0.354)* 0.340 (0.207–0.473)*
All postprandial 0.167 (0.123–0.211)* 0.186 (0.129–0.242)* 0.177 (0.094–0.259)* 0.134 (0.024–0.245)*
Difference pre-/postprandial‡ P  0.01 P  0.07 P  0.34 P  0.08
A1C variation explained† 40% 37% 48% 38%
C
All preprandial 0.257 (0.204–0.310)* 0.244 (0.178–0.310)* 0.136 (0.004–0.268)* 0.312 (0.176–0.447)*
All postprandial 0.163 (0.120–0.206)* 0.183 (0.128–0.239)* 0.182 (0.102–0.262)* 0.106 (0.008 to 0.220)
Nocturnal SMBG 0.071 (0.040–0.102)* 0.060 (0.022–0.098)* 0.117 (0.027–0.207)* 0.069 (0.019 to 0.156)
Difference pre-/postprandial
1 P  0.04 P  0.28 P  0.64 P  0.07
A1C variation explained† 41% 38% 50% 39%
A1C variation explained by
average blood glucose§ 53% 51% 56% 53%
Data are  coefﬁcients (in % A1C per mmol/l) from multiple linear regression models (95% CI), unless otherwise indicated. A: model including
mealtime measurements. B: model including mean of all pre- and postprandial values. C: model with both prandial and nocturnal blood
glucose. *P value for estimates 0.05. †The proportion of A1C variation (SD) explaned by the glucose features of each model. ‡P values from
test of difference between pre- and postprandial estimates. §For comparison, the A1C variation explained by average blood glucose is
illustrated.
R. BORG AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, JULY 2010 1589management is still debated. We found relatively weak
correlations between variability indexes and indexes of
fasting, postprandial, and mean glycemia, indicating that
the variability indexes convey different information. Fast-
ing glucose values had only a moderate correlation with
other indexes, conﬁrming that it is not a clear indicator of
general glycemia. The mean of all preprandial glucose
levels had a larger impact on A1C levels than postprandial
glucose levels in type 1 and type 2 diabetic patients.
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